Lipophagy and epigenetic alterations are related to metabolic dysfunction-associated steatotic liver disease progression in an experimental model

doi:10.4254/wjh.v16.i12.1468

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (736)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-1) series.

Item

Count

PDF

HTML

420

Figures (1-5)

Tables (1-1)

Sum=601

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=97

Dec 27, 2024 (publication date) through Jan 11, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Hepatol. Dec 27, 2024; 16(12): 1468-1479
Published online Dec 27, 2024. doi: 10.4254/wjh.v16.i12.1468

Full Size Figure Download Figure

Figure 4 Inflammation, fibrosis, and metabolic dysfunction-associated fatty liver disease status. A: Results after dividing the intervention group in two halves according to their inflammation status; B: Results after dividing the intervention group in two halves according to their fibrosis status; C: Results after dividing the intervention group in two halves according to their metabolic dysfunction-associated fatty liver disease status. Plin: Perilipin; Tfeb: Transcription factor EB; NAFLD: Non-alcoholic fatty liver disease.

Citation: Schütz F, Longo L, Keingeski MB, Filippi-Chiela E, Uribe-Cruz C, Álvares-da-Silva MR. Lipophagy and epigenetic alterations are related to metabolic dysfunction-associated steatotic liver disease progression in an experimental model. World J Hepatol 2024; 16(12): 1468-1479
URL: https://www.wjgnet.com/1948-5182/full/v16/i12/1468.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i12.1468